In This Article:
MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held virtually in Montreal, Quebec ("Meeting").
Election of Directors
Each director nominee listed in the Management Information Circular dated April 11, 2022 ("Circular") was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows:
| DIRECTOR NOMINEE | OUTCOME | VOTES | % FOR | VOTES | % | |||
| Jonathan Ross Goodman | Elected | 60,902,832 | 95.75% | 2,701,678 | 4.25% | |||
| James C. Gale | Elected | 63,265,174 | 99.47% | 339,336 | 0.53% | |||
| Samira Sakhia | Elected | 63,472,472 | 99.79% | 132,038 | 0.21% | |||
| Robert N. Lande | Elected | 60,537,287 | 95.18% | 3,067,223 | 4.82% | |||
| Michael J. Tremblay | Elected | 57,178,604 | 89.90% | 6,425,906 | 10.10% | |||
| Nicolás Sujoy | Elected | 60,678,074 | 95.40% | 2,926,436 | 4.60% | |||
| Janice Murray | Elected | 63,124,888 | 99.25% | 479,622 | 0.75% | |||
Appointment of external Auditors
Ernst & Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present or represented by proxy, and the directors were authorized to determine their remuneration. Shareholders present in person or represented by proxy at the Meeting voted as follows:
| OUTCOME | VOTES FOR | % FOR | VOTES WITHHELD | % WITHHELD |
| Appointed | 63,633,816 | 99.78% | 141,491 | 0.22% |
Approval of unallocated rights under the Corporation’s employee share purchase plan (“ESPP”)
The resolution to approve unallocated rights under the Corporation’s employee share purchase plan for the ensuing three years, as described in the Circular, was approved by a majority of the votes cast by the shareholders present or represented by proxy. Shareholders present in person or represented by proxy at the Meeting voted as follows:
| OUTCOME | VOTES FOR | % FOR | VOTES AGAINST | % AGAINST |
| Approved | 50,507,892 | 79.41% | 13,096,618 | 20.59% |
The results of the final votes regarding all matters subject to a vote during the Meeting will also be made available on SEDAR (www.sedar.com).
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.